A study to assess if gabapentine could prevent the postherpetic neuralgia in patient with Herpes zoster if treated the first 72 hour of the onset.

Registry ID

EUCTR2013-000521-31

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Gerencia de Atención Primaria de Mallorca

Start date

2013-12-26

Last update

2026-08-16

Conditions

• Postherpetic Neuralgia

Summary

To evaluate the efficacy of optimal doses of gabapentin for 5 weeks in the acute phase of herpes zoster in patients>= 50 years with moderate to severe pain added to the usual treatment to reduce the percentage of patients without post-herpetic neuralgia at 12 weeks.

Locations

• , , Spain

Related clinical trials

• Y-4 to Treat the Postherpetic Neuralgia
• The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster
• Erector Spinae Plane Block Versus Transcutaneous Radiofrequency in Postherpetic Neuralgia
• Efficacy of Transcutaneous Pulsed Radiofrequency in Postherpetic Neuralgia
• Clinical Trial of the Safety and Efficacy of Peripheral Nerve Stimulation in the Treatment of Peripheral Neuropathic Pain.
• The Effectiveness of Ultra-Sound Guided Erector Spinae Block With Betamethasone for Management of Truncal Chronic Post Herpetic Neuralgia.

View on source registry